Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALT-801 in muscle invasive or metastatic urothelial cancer
NCT01326871Phase 2Completed
- Sponsor
- Altor BioScience Corporation
- Start
- Sep 2011
- Primary completion
- Apr 2016
- Countries
- 1
01
Overview
A Phase 2 trial of pemvidutide in urothelial carcinoma (UC), sponsored by Altor BioScience Corporation. Started Sep 2011; status: completed.
02
Drugs
pemvidutide
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT01326871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01326871.